Comparing gonadotrophin releasing hormone agonist versus human chorionic gonadotrophin in improving IVF outcome

GnRH agonist versus human chorionic gonadotropin for triggering ovulation in antagonist cycles: randomized controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201506001132105

Enrollment

190

Registered

2015-05-07

Start date

2015-06-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fertility-female Infertility

Interventions

GnRH agonist "triptorelin"

human chorionic gonadotropin

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 18 - 35 years old age. High responder PCO patients defined as having 18 follicles or more on the day of final oocyte maturation, measuring 11 mm or more in mean diameter and or estradiol level 4000 pg/ml or more.

Exclusion criteria

Exclusion criteria: - women with uterine anomalies. - Women with uterine fibroids. - Women diagnosed with endometriosis. - Male factor of infertility requiring testicular biopsy.

Design outcomes

Primary

Measure	Time frame
Ongoing pregnancy rate	—

Secondary

Measure	Time frame
Clinical pregnancy rate;Miscarriage rate;Number of retrieved oocytes;Number of MII oocytes	—

Countries

Egypt

Contacts

Public ContactMagdy Mostafa

Prof. Ob/Gyn, Faculty of Medicine, Cairo University

imagdy@kasralainy.edu.eg(20) 100 520 730 5

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026